Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

IGC Pharma (IGC) Accumulated Depreciation & Amortization (2016 - 2025)

Historic Accumulated Depreciation & Amortization for Pharma (IGC) over the last 14 years, with Q3 2025 value amounting to $1.7 million.

  • Pharma's Accumulated Depreciation & Amortization fell 3398.92% to $1.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year decrease of 3398.92%. This contributed to the annual value of $2.7 million for FY2025, which is 1027.85% up from last year.
  • Latest data reveals that Pharma reported Accumulated Depreciation & Amortization of $1.7 million as of Q3 2025, which was down 3398.92% from $2.8 million recorded in Q2 2025.
  • In the past 5 years, Pharma's Accumulated Depreciation & Amortization registered a high of $3.3 million during Q4 2021, and its lowest value of $1.7 million during Q3 2025.
  • Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $2.6 million (2024), whereas its average is $2.5 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first crashed by 4581.82% in 2022, then surged by 3014.54% in 2023.
  • Over the past 5 years, Pharma's Accumulated Depreciation & Amortization (Quarter) stood at $3.3 million in 2021, then crashed by 45.82% to $1.8 million in 2022, then surged by 30.15% to $2.3 million in 2023, then increased by 11.77% to $2.6 million in 2024, then plummeted by 34.22% to $1.7 million in 2025.
  • Its Accumulated Depreciation & Amortization stands at $1.7 million for Q3 2025, versus $2.8 million for Q2 2025 and $2.7 million for Q1 2025.